MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs

ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company’s approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders.

“We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility.”

MaxCyte’s ExPERT™ instrument portfolio represents the next generation of clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.

About MaxCyte
At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Specifically, there is no assurance that MaxCyte will receive additional program-related revenue or other revenue under this SPL.

Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

US Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com